Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients
Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients
复制标题
DOI：
10.1016/s0022-5223(00)70188-7
复制
发表时间：
2000-02-01
影响因子：
6
通讯作者：
Shaddy, RE
中科院分区：
文献类型：
--
作者：
Hawkins, JA;Breinholt, JP;Shaddy, RE
Objectives: Very little is known regarding the immune response to cryo-preserved allograft valves and patch material used in the surgical repair of congenital heart defects.Methods: We prospectively measured the frequency of panel reactive antibodies directed against HLA class I (HLA-A, B, and C) and class II (HLA-DR/DQ) alloantigens in 24 children receiving cryopreserved allografts. We compared them with results in II previously reported control patients. Sixteen of the study patients underwent placement of a valved conduit (II. pulmonic, 5 aortic) between the right ventricle and pulmonary arteries, 6 underwent patch angioplasty of stenotic vessels with cryopreserved pulmonary artery and 2 underwent placement of a pulmonary monocusp patch. Study patients had panel reactive antibodies measured before, 1 month, 3 months, and 1 year after the operation.Results: With allograft implantation, panel reactive antibodies increased from 1.9% +/- 5% before the operation to 62% +/- 33% at 31 +/- 8 days after the operation, 92% +/- 15% at 3.3 +/- 0.6 months after the operation, and 85% +/- 18% at 1.1 +/- 0.2 years after the operation. The control group showed no change in panel reactive antibodies, with a level of 1.6% +/- 1% before the operation, 3.2% +/- 1% 28 +/- 5 days after the operation, and 1.7% +/- 1% 2.7 +/- 0.3 months after the operation. Class II antibodies (anti-HLA-DR/DQ) rose to 49% +/- 35% at 30 +/- 8 days and 70% +/- 26% at 3.3 +/- 0.6 months after the operation,Conclusions: Cryopreserved allograft material induces a marked response that involves both class I and class II anti-HLA antibodies within 3 months after operation in children. This alloantibody response may represent a form of "rejection," may have implications for those who require subsequent cardiac transplantation, and may play a role in early allograft failure.
